LISATHYONE 600 mg/3 ml Powder and solvent for solution for injection

What is LISATHYONE 600 mg/3 ml

LISATHYONE 600 mg/3 ml is a parenteral preparation that contains Miglitol, an oral alpha-glucosidase inhibitor commonly used to manage postprandial hyperglycemia in patients with type 2 diabetes mellitus. However, the injectable form, although uncommon for this drug class, may be used in experimental or hospital-specific protocols where intravenous modulation of carbohydrate absorption is required, or where oral administration is not feasible. It is supplied as a powder to be reconstituted with a provided solvent ampoule prior to injection.

• Generic Name: Miglitol
• Form: Powder and Solvent for Injection
• Strength: 600 mg of Miglitol per 3 mL dose
• Pharmacologic Class: Alpha-glucosidase Inhibitor
• Therapeutic Use: Management of postprandial hyperglycemia in diabetes mellitus

Miglitol delays carbohydrate digestion and absorption in the small intestine, helping to control blood sugar spikes after meals. It is most commonly used in oral form, and injectable formulations are rare and should be used under specialist guidance only.

How to use LISATHYONE 600 mg/3 ml

This medicine is intended for intravenous (IV) or intramuscular (IM) injection after proper reconstitution. Administration should only be performed by a trained healthcare provider.

• Remove the vial and solvent ampoule from their packaging
• Inject the provided solvent into the vial containing the powder
• Gently swirl until fully dissolved (avoid shaking vigorously)
• Withdraw the solution into a sterile syringe
• Administer the dose via IV or IM route as per physician’s instructions

Use the solution immediately after reconstitution. Do not store or reuse any remaining solution.

Mode of Action LISATHYONE 600 mg/3 ml

Miglitol works by inhibiting enzymes in the brush border of the small intestine that break down complex carbohydrates into glucose. Specifically, it inhibits alpha-glucosidase enzymes such as sucrase, maltase, and isomaltase.

• Delays the digestion of disaccharides and complex carbohydrates
• Slows glucose absorption and reduces post-meal blood sugar peaks
• Does not stimulate insulin secretion directly

Because of this mechanism, miglitol is often used alongside other antidiabetic medications, particularly in patients whose main issue is postprandial glucose control.

LISATHYONE 600 mg/3 ml Interactions LISATHYONE 600 mg/3 ml

Miglitol may interact with several medications that either enhance or diminish its effectiveness. Notable interactions include:

• Digestive enzymes (e.g., amylase, pancreatin): Reduce miglitol effectiveness
• Insulin or sulfonylureas: Increased risk of hypoglycemia when used concurrently
• Activated charcoal: May reduce absorption of miglitol
• Propranolol or other beta-blockers: May mask signs of hypoglycemia

Patients should inform their healthcare provider of all medications and supplements before starting LISATHYONE.

Dosage of LISATHYONE 600 mg/3 ml

Since this is a specialized injectable form, dosage must be determined by a healthcare provider. Typical oral doses of Miglitol range from 25–100 mg three times daily with meals. However:

• IV/IM dose: 600 mg (reconstituted in 3 mL solvent), used under physician supervision
• Frequency: As needed depending on clinical protocol and blood glucose monitoring
• Adjustments: May be required in renal impairment or in combination with other hypoglycemic agents

Always follow the specific dosage and frequency as prescribed by the treating physician.

Possible side effects of LISATHYONE 600 mg/3 ml

Like other alpha-glucosidase inhibitors, Miglitol may cause gastrointestinal discomfort. Injectable forms may also have local or systemic reactions.

• Common: Flatulence, bloating, abdominal cramps, and diarrhea
• Injection site: Redness, pain, or swelling
• Metabolic: Risk of hypoglycemia (especially if combined with insulin or sulfonylureas)
• Rare: Hepatic enzyme elevation, allergic skin reactions

Side effects usually subside as the body adjusts. Severe or persistent symptoms should be reported.

LISATHYONE 600 mg/3 ml Contraindications LISATHYONE 600 mg/3 ml

LISATHYONE (Miglitol) is not suitable for everyone. The following are contraindications:

• Hypersensitivity to Miglitol or any formulation components
• Chronic intestinal disorders (e.g., inflammatory bowel disease, colonic ulceration)
• Partial intestinal obstruction or predisposition to bowel obstruction
• Renal impairment (use with caution and dose adjustment)
• Pregnancy and lactation (safety not fully established)

A full medical evaluation is necessary before initiating treatment.

Storage of LISATHYONE 600 mg/3 ml

• Store powder vials and solvent at a temperature below 25°C
• Protect from light and moisture
• Do not freeze the powder or solvent
• Use immediately after reconstitution
• Keep out of reach of children

Inspect vials before use. Do not use if the powder is discolored or if the solvent ampoule is cracked or leaking.